Serum cytokines and creatinine/cystatin C ratio as prognostic biomarkers in advanced cancer patients treated with anti-PD-1/PD-L1 therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Serum cytokines and creatinine/cystatin C ratio as prognostic biomarkers in advanced cancer patients treated with anti-PD-1/PD-L1 therapy ; volume:32 ; number:6 ; day:22 ; month:5 ; year:2024 ; pages:1-13 ; date:6.2024
Supportive care in cancer ; 32, Heft 6 (22.5.2024), 1-13, 6.2024
- Urheber
-
Jin, Shan-xiu
Liu, Bo-Na
Ji, Hong-juan
Wu, Jing-ran
Li, Bao-lei
Gao, Xiao-li
Li, Na
Zheng, Zhen-dong
Du, Cheng
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00520-024-08525-z
- URN
-
urn:nbn:de:101:1-2410100728501.744537895859
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Jin, Shan-xiu
- Liu, Bo-Na
- Ji, Hong-juan
- Wu, Jing-ran
- Li, Bao-lei
- Gao, Xiao-li
- Li, Na
- Zheng, Zhen-dong
- Du, Cheng
- SpringerLink (Online service)
Ähnliche Objekte (12)
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review
Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review
Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review